All Updates

All Updates

icon
Filter
Product updates
Beam Therapeutics doses first patient with BEAM-201 in Phase I/II trial
Human Gene Editing
Sep 5, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Human Gene Editing

Human Gene Editing

Sep 5, 2023

Beam Therapeutics doses first patient with BEAM-201 in Phase I/II trial

Product updates

  • Massachusetts-based gene-editing startup Beam Therapeutics has dosed its first patient in a Phase I/II clinical trial with BEAM-201, a quadruplex base-edited allogeneic chimeric antigen receptor T (CAR-T)-cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL).

  • The T-ALL/T-LL patient is reportedly the company’s first patient to be dosed with its drug candidate and the first patient in the US to undergo a base editing therapy. The patient enrollment for the Phase I/II clinical trial for BEAM-201 is ongoing across several sites.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.